Telix expects sustained growth in 2026, driven by strong Gozellix adoption, expanded global market access, and integration of ARTMS technology to enhance efficiency. Reported ongoing engagement with both the FDA and EMA regarding regulatory resubmissions for TLX101-Px and TLX250-Px, indicating active dialogue but no reported approval setbacks.